MCID: CCN002
MIFTS: 48

Cocaine Abuse

Categories: Mental diseases

Aliases & Classifications for Cocaine Abuse

MalaCards integrated aliases for Cocaine Abuse:

Name: Cocaine Abuse 12 54 15 71
Cocaine-Related Disorders 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:809
ICD9CM 34 305.6 305.60
MeSH 43 D019970
SNOMED-CT 67 78267003
ICD10 32 F14.1
UMLS 71 C0009171 C0236736

Summaries for Cocaine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cocaine despite negative consequences.

MalaCards based summary : Cocaine Abuse, also known as cocaine-related disorders, is related to avoidant personality disorder and antisocial personality disorder. An important gene associated with Cocaine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Neuroscience. The drugs Risperidone and Amantadine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and heart, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Cocaine Abuse

Diseases related to Cocaine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 393)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.2 SLC6A4 SLC6A3 DRD2
2 antisocial personality disorder 30.9 SLC6A4 SLC6A3 PRL MAOB DRD2
3 alcohol use disorder 30.8 SLC6A4 SLC6A3 HTR3A DRD2 BDNF
4 eating disorder 30.8 SLC6A4 SLC6A3 DRD2 BDNF
5 conduct disorder 30.7 SLC6A4 SLC6A3 DRD2 DBH
6 hyperprolactinemia 30.7 PRL DRD2 DBH
7 cocaine dependence 30.7 SLC6A4 SLC6A3 PRL OPRK1 MAOB DRD2
8 personality disorder 30.6 SLC6A4 SLC6A3 PRL MAOB HTR3A DRD2
9 galactorrhea 30.6 PRL DRD2
10 anorexia nervosa 30.4 SLC6A4 SLC6A2 PRL BDNF
11 opiate dependence 30.4 SLC6A4 SLC6A3 OPRK1 NGF DRD2
12 adrenal gland pheochromocytoma 30.4 NGF BDNF
13 drug dependence 30.4 SLC6A4 SLC6A3 OPRK1 HTR3A DRD2 BDNF
14 tic disorder 30.3 SLC6A4 SLC6A3 SLC18A2 DRD2
15 traumatic brain injury 30.3 IL6 DRD2 BDNF
16 brain injury 30.3 IL6 DRD2 BDNF
17 sexual disorder 30.3 SLC6A4 PRL HTR3A DRD2
18 schizoaffective disorder 30.2 SLC6A4 PRL DRD2 BDNF
19 sudden infant death syndrome 30.2 SLC6A4 IL6 HTR3A BDNF
20 sleep apnea 30.2 SLC6A4 IL6 BDNF
21 paranoid schizophrenia 30.1 SLC6A4 PRL IL6 BDNF
22 mental depression 30.1 SLC6A4 SLC6A3 SLC6A2 IL6 HTR3A DRD2
23 opioid addiction 30.0 OPRK1 DRD2
24 movement disease 30.0 SNCA SLC6A3 SLC18A2 MAOB DRD2
25 post-traumatic stress disorder 30.0 SLC6A4 MAOB DRD2 DBH BDNF
26 borderline personality disorder 29.9 SLC6A4 SLC6A3 PRL HTR3A DRD2 BDNF
27 substance abuse 29.9 SLC6A4 SLC6A3 PRL OPRK1 MOBP DRD2
28 dystonia 29.8 SLC6A3 SLC18A2 PRL MAOB DRD2 DBH
29 panic disorder 29.7 SLC6A4 SLC6A3 SLC6A2 PRL HTR3A DRD2
30 huntington disease 29.6 SNCA SLC6A3 NGF MAOB DRD2 BDNF
31 sleep disorder 29.6 SNCA SLC6A4 SLC6A3 PRL IL6 DRD2
32 substance dependence 29.5 SLC6A4 SLC6A3 OPRK1 IL6 DRD2 BDNF
33 psychotic disorder 29.4 SLC6A4 SLC6A3 SLC18A2 PRL MAOB HTR3A
34 dementia 29.4 SNCA SLC6A3 NGF MAOB DRD2 BDNF
35 pheochromocytoma 29.4 SLC6A2 PRL NGF MAOB IL6 DRD2
36 major depressive disorder 29.4 SLC6A4 SLC6A3 SLC6A2 PRL NGF MAOB
37 narcolepsy 29.3 SLC6A4 SLC6A3 SLC6A2 SLC18A2 IL6 HTR3A
38 alcohol dependence 29.0 SNCA SLC6A4 SLC6A3 SLC6A2 SLC18A2 PRL
39 anxiety 28.8 SLC6A4 SLC6A3 SLC6A2 PRL OPRK1 NGF
40 bipolar disorder 28.8 SLC6A4 SLC6A3 SLC6A2 SLC18A2 PRL NGF
41 body mass index quantitative trait locus 11 28.7 SLC6A3 SLC6A2 PRL MAOB IL6 DRD2
42 amyotrophic lateral sclerosis 1 28.7 SNCA SLC6A3 SIGMAR1 NGF MAOB BDNF
43 attention deficit-hyperactivity disorder 28.7 SNCA SLC6A4 SLC6A3 SLC6A2 SLC18A2 PRL
44 alzheimer disease 28.4 SNCA SLC6A4 SLC6A3 NGF MAOB IL6
45 parkinson disease, late-onset 28.4 SNCA SLC6A4 SLC6A3 SLC6A2 SLC18A2 NGF
46 migraine with or without aura 1 28.4 SLC6A4 SLC6A3 PRL OPRK1 NGF MAOB
47 disease of mental health 28.3 SNCA SLC6A4 SLC6A3 OPRK1 NGF IL6
48 schizophrenia 27.5 SNCA SLC6A4 SLC6A3 SLC6A2 SLC18A2 SIGMAR1
49 schizophrenia 5 10.6 PRL DRD2
50 vasculitis 10.6

Graphical network of the top 20 diseases related to Cocaine Abuse:



Diseases related to Cocaine Abuse

Symptoms & Phenotypes for Cocaine Abuse

GenomeRNAi Phenotypes related to Cocaine Abuse according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR3A SIGMAR1 SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR3A SIGMAR1 SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR3A SIGMAR1 SLC6A4

MGI Mouse Phenotypes related to Cocaine Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 BDNF CARTPT DBH DRD2 HTR3A IL6
2 homeostasis/metabolism MP:0005376 10.22 BCHE BDNF CARTPT DBH DRD2 HTR3A
3 growth/size/body region MP:0005378 10.15 BDNF CARTPT DBH DRD2 HTR3A IL6
4 endocrine/exocrine gland MP:0005379 10.14 BDNF CARTPT DBH DRD2 HTR3A IL6
5 integument MP:0010771 10.07 BDNF DBH DRD2 HTR3A IL6 NGF
6 nervous system MP:0003631 10.06 BDNF DBH DRD2 HTR3A IL6 MAOB
7 reproductive system MP:0005389 9.61 BCHE BDNF DRD2 HTR3A IL6 OPRK1
8 taste/olfaction MP:0005394 9.1 BDNF DRD2 GRK3 SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Cocaine Abuse

Drugs for Cocaine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
2
Amantadine Approved Phase 4 768-94-5 2130
3
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
8
Choline Approved, Nutraceutical Phase 4 62-49-7 305
9 Calcium, Dietary Phase 4
10 calcium channel blockers Phase 4
11 Antipsychotic Agents Phase 4
12 Dopamine Antagonists Phase 4
13 Tranquilizing Agents Phase 4
14 Gastrointestinal Agents Phase 4
15 Antiparkinson Agents Phase 4
16 Nootropic Agents Phase 4
17 Sodium Channel Blockers Phase 4
18 Antimanic Agents Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Cytidine Diphosphate Choline Phase 4
21 Quetiapine Fumarate Phase 4 111974-72-2
22 Antimetabolites Phase 4
23 Hypolipidemic Agents Phase 4
24 Lecithin Phase 4
25 Lipid Regulating Agents Phase 4
26
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3 52485-79-7 40400 644073
27
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
28
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
29
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
30
Levodopa Approved Phase 2, Phase 3 59-92-7 6047
31
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
32
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
33
Topiramate Approved Phase 2, Phase 3 97240-79-4 5284627
34
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359
35
Entacapone Approved, Investigational Phase 2, Phase 3 130929-57-6 5281081
36
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
37
Biperiden Approved, Investigational Phase 3 514-65-8 2381
38
Nicotine Approved Phase 3 54-11-5 942 89594
39
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
40
Bupropion Approved Phase 2, Phase 3 34911-55-2, 34841-39-9 444
41
Methadone Approved Phase 2, Phase 3 76-99-3 4095
42 Serotonin Receptor Agonists Phase 2, Phase 3
43 Serotonin Uptake Inhibitors Phase 2, Phase 3
44 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
45 Hormone Antagonists Phase 2, Phase 3
46 Progestins Phase 2, Phase 3
47 Anti-Infective Agents Phase 3
48 Cytochrome P-450 CYP3A Inducers Phase 3
49 Parasympatholytics Phase 3
50 Muscarinic Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 414)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
3 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
4 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
5 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
6 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
7 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
8 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
9 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
10 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
11 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
12 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction: The Role of Glutamate Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
13 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
14 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Disorder Recruiting NCT02927236 Phase 4
15 Brain Imaging: Cocaine Effects & Medication Development Withdrawn NCT00000270 Phase 4 Cocaine
16 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
17 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
18 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
19 Effect of Nefazodone on Relapse in Females With Cocaine Abuse Completed NCT00000293 Phase 3 Nefazodone
20 Dose Response Trial of Pergolide for Cocaine Dependence Completed NCT00000248 Phase 3 Pergolide
21 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
22 A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
23 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts Completed NCT00000216 Phase 3 Buprenorphine
24 Combining Behavioral Treatment With Agonist Maintenance Completed NCT00000311 Phase 3 Buprenorphine;methadone
25 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
26 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
27 Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
28 Treatment of Adult ADHD in Methadone Patients Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
29 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
30 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
31 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
32 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
33 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
34 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
35 Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
36 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
37 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
38 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
39 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
40 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
41 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
42 Bupropion-Enhanced CM for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
43 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Active, not recruiting NCT02774954 Phase 3
44 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
45 Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence. Unknown status NCT01397266 Phase 2
46 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
47 Efeitos da Estimulacao Magnetica Transcrania de Repeticao ( EMTr) no Tratamento da Dependencia ao Uso de Cocaina Unknown status NCT01259362 Phase 2
48 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
49 Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
50 Pemoline for Cocaine Abuse Completed NCT00000282 Phase 2 Pemoline

Search NIH Clinical Center for Cocaine Abuse

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Maprotiline
Maprotiline Hydrochloride

Cochrane evidence based reviews: cocaine-related disorders

Genetic Tests for Cocaine Abuse

Anatomical Context for Cocaine Abuse

MalaCards organs/tissues related to Cocaine Abuse:

40
Brain, Cortex, Heart, Testes, Prefrontal Cortex, Pituitary, Kidney

Publications for Cocaine Abuse

Articles related to Cocaine Abuse:

(show top 50) (show all 2275)
# Title Authors PMID Year
1
Disulfiram: an old therapeutic with new applications. 54 61
20201810 2010
2
Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation. 54 61
19402731 2009
3
Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines. 54 61
19253970 2009
4
Expression of transcripts for myelin related genes in postmortem brain from cocaine abusers. 54 61
18357522 2009
5
Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. 54 61
20230764 2009
6
Nonhuman primate neuroimaging and cocaine medication development. 54 61
19086766 2008
7
Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. 54 61
18579413 2008
8
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. 54 61
17897630 2008
9
Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? 54 61
17291372 2007
10
Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. 54 61
16110277 2005
11
Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. 54 61
15879005 2005
12
PET imaging of dopamine D2 receptors in monkey models of cocaine abuse: genetic predisposition versus environmental modulation. 54 61
16055768 2005
13
Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. 54 61
15740791 2005
14
Conformational analysis of methylphenidate: comparison of molecular orbital and molecular mechanics methods. 54 61
15865064 2004
15
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. 54 61
12801223 2003
16
Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. 54 61
12565970 2003
17
The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. 54 61
11408518 2001
18
Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. 54 61
10881032 2000
19
Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. 54 61
10869397 2000
20
3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter. 54 61
10732975 2000
21
Dopamine transporter mRNA in autopsy studies of chronic cocaine users. 54 61
10581411 1999
22
Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. 54 61
8995326 1997
23
[The dopamine transporter: characterization and physiopathologic implications]. 54 61
8674469 1995
24
A 50-Year-Old Woman With Confusion and Facial Rash. 61
32033659 2020
25
MicroRNA134 of Ventral Hippocampus Is Involved in Cocaine Extinction-Induced Anxiety-like and Depression-like Behaviors in Mice. 61
32004865 2020
26
A novel differential scanning fluorimetry analysis of a humanized anti-cocaine mAb and its ligand binding characteristics. 61
31634480 2020
27
Systemic Safety of a Recombinant AAV8 Vector for Human Cocaine Hydrolase Gene Therapy: A Good Laboratory Practice Preclinical Study in Mice. 61
31650869 2020
28
Sex differences in the vulnerability to cocaine's addictive effects after early-life stress in mice. 61
31918976 2020
29
Brown Bowel Syndrome: A Multi-institutional Case Series. 61
31985498 2020
30
Cross-reinstatement between 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using conditioned place preference. 61
31991149 2020
31
Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder. 61
31634677 2020
32
The Hotel Room Purchase Task: Effects of Gender and Partner Desirability on Demand for Hypothetical Sex in Individuals with Disordered Cocaine Use and Controls. 61
31989411 2020
33
Better executive function is independently associated with full HIV suppression during combination therapy. 61
31764096 2019
34
Newly Developed Dopamine D3 Receptor Antagonists, R-VK4-40 and R-VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats. 61
31562201 2019
35
Melatonin decreases cocaine-induced locomotor activity in pinealectomized rats. 61
31859790 2019
36
Cocaine: A Provoking Risk Factor in Venous Thromboembolism. 61
32025439 2019
37
A new classification for septal perforation and effects of treatment methods on quality of life. 61
30057254 2019
38
Genetic Variant in the CRH-binding Protein Gene (CRHBP) is Associated With Cessation of Cocaine Use in Methadone Maintenance Patients With Opioid Addiction. 61
30844877 2019
39
Structural analysis of free and liganded forms of the Fab fragment of a high-affinity anti-cocaine antibody, h2E2. 61
31702583 2019
40
Cocaine-induced ANCA-associated renal disease: a case-based review. 61
31401698 2019
41
The treatment of cocaine use disorder. 61
31663022 2019
42
Recent cocaine use and memory impairment in HIV. 61
31661322 2019
43
Sensorimotor Gating in Cocaine-Related Disorder with Comorbid Schizophrenia or Antisocial Personality Disorder. 61
31287382 2019
44
Dynamic interaction of genetic risk factors and cocaine abuse in the background of Parkinsonism - a case report. 61
31660902 2019
45
Nasal Septum Defects Detected on Postmortem Computed Tomography. 61
30985333 2019
46
Miniaturized analytical platform for cocaine detection in oral fluids by MicroNIR/Chemometrics. 61
31171220 2019
47
Clonidine, an α2 adrenergic receptor agonist, disrupts reconsolidation of a cocaine-paired environmental memory. 61
31386639 2019
48
Pneumomediastinum, subcutaneous and epidural emphysema due to cocaine abuse. 61
31558267 2019
49
Modulation of striatal dopamine dynamics by cocaine self-administration and amphetamine treatment in female rats. 61
31111573 2019
50
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms. 61
31437433 2019

Variations for Cocaine Abuse

Expression for Cocaine Abuse

Search GEO for disease gene expression data for Cocaine Abuse.

Pathways for Cocaine Abuse

Pathways related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 SLC6A3 SLC18A2 SLC17A8 MAOB GRK3 DRD2
2 12.38 SNCA SIGMAR1 NGF GRK3 DBH CARTPT
4 11.93 SLC6A4 NGF IL6 HTR3A BDNF
5 11.87 SLC6A4 SLC18A2 MAOB HTR3A
6
Show member pathways
11.77 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8
7 11.63 SLC18A2 NGF BDNF
8
Show member pathways
11.43 SLC6A3 SLC18A2 MAOB DRD2 BDNF
9 11.37 NGF DRD2 BDNF
10 11.21 SNCA SLC6A3 MAOB
11 11.12 SLC6A4 SLC18A2 HTR3A
12
Show member pathways
11.09 SLC6A4 SLC6A3 SLC6A2 DBH
13
Show member pathways
11.07 SLC6A4 SLC6A3 BCHE
14 10.97 SLC6A2 SLC18A2 DBH
15 10.88 PRL DRD2 CARTPT
16
Show member pathways
10.53 SLC6A4 SLC6A3 SLC6A2 SLC18A2 MAOB DRD2

GO Terms for Cocaine Abuse

Cellular components related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.11 SNCA PRL NGF IL6 DBH CARTPT
2 integral component of plasma membrane GO:0005887 10.02 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8 SIGMAR1
3 cytoplasmic vesicle GO:0031410 9.98 SLC18A2 SLC17A8 SIGMAR1 NGF DRD2 DBH
4 neuron projection GO:0043005 9.89 SLC6A4 SLC6A3 SLC6A2 SLC17A8 HTR3A
5 axon GO:0030424 9.8 SNCA SLC6A3 NGF HTR3A DRD2 BDNF
6 synaptic vesicle GO:0008021 9.76 SNCA SLC18A2 NGF BDNF
7 synaptic vesicle membrane GO:0030672 9.71 SNCA SLC18A2 SLC17A8 DRD2
8 axon terminus GO:0043679 9.65 SNCA SLC17A8 DRD2
9 integral component of presynaptic membrane GO:0099056 9.46 SLC6A4 SLC6A3 HTR3A DRD2
10 dopaminergic synapse GO:0098691 9.43 SLC6A3 SLC18A2 DRD2
11 integral component of postsynaptic membrane GO:0099055 9.26 SLC6A4 SLC6A3 HTR3A DRD2
12 synapse GO:0045202 9.23 SNCA SLC6A4 SLC17A8 SIGMAR1 OPRK1 HTR3A

Biological processes related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 PRL OPRK1 IL6 HTR3A GRK3 DRD2
2 response to ethanol GO:0045471 9.8 SLC6A3 MAOB HTR3A DRD2
3 response to drug GO:0042493 9.8 SNCA SLC6A4 SLC6A3 SLC6A2 MAOB DRD2
4 modulation of chemical synaptic transmission GO:0050804 9.79 NGF DRD2 BDNF
5 response to toxic substance GO:0009636 9.78 SLC6A4 SLC18A2 MAOB DRD2
6 excitatory postsynaptic potential GO:0060079 9.77 SNCA HTR3A DRD2
7 locomotory behavior GO:0007626 9.77 SLC6A3 SLC18A2 OPRK1 DRD2 DBH
8 memory GO:0007613 9.76 SLC6A4 NGF DBH BDNF
9 response to amphetamine GO:0001975 9.72 SLC18A2 DRD2 DBH
10 response to cocaine GO:0042220 9.71 SNCA SLC6A3 HTR3A DRD2
11 chemical synaptic transmission GO:0007268 9.7 SNCA SLC6A2 SLC18A2 OPRK1 HTR3A DBH
12 neuron cellular homeostasis GO:0070050 9.65 SLC6A2 IL6
13 prepulse inhibition GO:0060134 9.65 SLC6A3 DRD2
14 behavioral response to ethanol GO:0048149 9.65 DRD2 DBH
15 dopamine metabolic process GO:0042417 9.64 SNCA DRD2
16 nerve development GO:0021675 9.64 NGF BDNF
17 negative regulation of bone resorption GO:0045779 9.63 IL6 CARTPT
18 neurotransmitter biosynthetic process GO:0042136 9.63 SLC6A4 SLC6A3
19 nerve growth factor signaling pathway GO:0038180 9.62 NGF BDNF
20 dopamine biosynthetic process GO:0042416 9.61 SNCA SLC6A3
21 opioid receptor signaling pathway GO:0038003 9.61 SIGMAR1 OPRK1
22 dopamine catabolic process GO:0042420 9.61 SLC6A3 MAOB DBH
23 adenohypophysis development GO:0021984 9.6 SLC6A3 DRD2
24 neurotransmitter reuptake GO:0098810 9.58 SLC6A4 SLC6A2
25 positive regulation of collateral sprouting GO:0048672 9.58 NGF BDNF
26 dopamine transport GO:0015872 9.57 SLC6A3 SLC18A2
27 neurotransmitter loading into synaptic vesicle GO:0098700 9.56 SLC18A2 SLC17A8
28 norepinephrine uptake GO:0051620 9.54 SLC6A3 SLC6A2
29 serotonin uptake GO:0051610 9.52 SLC6A4 SLC18A2
30 norepinephrine transport GO:0015874 9.51 SLC6A3 SLC6A2
31 dopamine uptake involved in synaptic transmission GO:0051583 9.5 SNCA SLC6A3 SLC6A2
32 neurotransmitter transport GO:0006836 9.35 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8
33 monoamine transport GO:0015844 8.92 SLC6A4 SLC6A3 SLC6A2 SLC18A2

Molecular functions related to Cocaine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.61 SLC6A3 SIGMAR1 DRD2
2 dopamine binding GO:0035240 9.48 SLC6A3 DRD2
3 serotonin binding GO:0051378 9.46 SLC6A4 HTR3A
4 symporter activity GO:0015293 9.46 SLC6A4 SLC6A3 SLC6A2 SLC17A8
5 opioid receptor activity GO:0004985 9.4 SIGMAR1 OPRK1
6 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A2
7 serotonin:sodium symporter activity GO:0005335 9.32 SLC6A4 SLC18A2
8 norepinephrine:sodium symporter activity GO:0005334 9.26 SLC6A3 SLC6A2
9 neurotransmitter:sodium symporter activity GO:0005328 9.13 SLC6A4 SLC6A3 SLC6A2
10 monoamine transmembrane transporter activity GO:0008504 8.92 SLC6A4 SLC6A3 SLC6A2 SLC18A2

Sources for Cocaine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....